Skip to main content
Back to News
neuroClues closed a €10M Series A, bringing total capital to €25M, to commercialise its CE‑marked ey...
Funding
1 min read

neuroClues closed a €10M Series A, bringing total capital to €25M, to commercialise its CE‑marked ey...

The AMW Read

The article updates the player map for Vertical AI - Healthcare/Bio with a mid-sized Series A round for a specialized diagnostic hardware/AI company.
NoveltySignificance
Healthcare & Bio · Player Map
neuroClues
neuroClues

AI in Healthcare

View Company Profile

neuroClues closed a €10M Series A, bringing total capital to €25M, to commercialise its CE‑marked eye‑tracking device that delivers AI‑derived neurological biomarkers in a 10‑minute exam. With 30+ units already deployed across seven European countries, the platform aims to cut misdiagnosis rates (currently 1 in 5) and enable earlier intervention for diseases like Parkinson's, where neuron loss can reach 65% before correct diagnosis. The funding also earmarks U.S. regulatory preparation, positioning neuroClues as a scalable, data‑driven alternative to costly imaging.

Explore neuroCluesRead Original

How This Connects

Based on Healthcare & Bio · Player Map

  1. 19h agoIsomorphic Labs explores funding at a valuation of at least $40 billionIsomorphic Labs
  2. 1w agoApheris and Ginkgo launch antibody AI consortium with four pharma companiesApheris
  3. 1w agoEnveda raises $311 million to advance AI-discovered natural-molecule drugsEnveda
  4. 3w agoLevel Five, a game developer, has issued a public apology after facing criticism for what it called...Level Five
  5. 6mo agoneuroClues closed a €10M Series A, bringing total capital to €25M, to commercialise its CE‑marked ey... · THIS ARTICLE

More news from neuroClues

Stay updated with the latest news and announcements from neuroClues.

View all neuroClues news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard